Advancements in the molecular understanding of major depressive disorder uncovering novel targets with therapeutic promise: focus on recurrence of illness

The future of recurrent MDD therapeutics resides in multi-targeting the ROI-associated pathways with NIMETOX-guided interventions aimed at attenuating immune sensitization, rectifying metabolic dysfunction, reducing oxidative toxicity, and concurrently restoring neuroplasticity. The development of such integrative therapies is an urgent imperative if we are to alter the natural trajectory of recurrent depression.